Influence of weight reduction by sibutramine on female sexual function

International Journal of Obesity

Volumn 30, Issue 5, 2006, Pages 758-763

  Kim, K K ^a   Kang, H C ^a   Kim, S S ^a   Youn, B B ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Female sexual function; FSFI; Sibutramine; Weight reduction

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ADULT; AROUSAL; ARTICLE; BEHAVIOR THERAPY; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; OBESITY; ORGASM; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL SATISFACTION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ANTIDEPRESSIVE AGENTS; APPETITE DEPRESSANTS; BEHAVIOR THERAPY; BODY COMPOSITION; COMBINED MODALITY THERAPY; CYCLOBUTANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KOREA; MIDDLE AGED; OBESITY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 33646373936     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803198     Document Type: Article

References (38)

1. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American Psychiatric Association: Washington, DC, 1994.
2. Brassil DF, Keller M. Female sexual dysfunction: definitions, causes, and treatment. Urol Nurs 2002; 22: 237-244, 284; quiz 245, 248.
3. Berman JR, Bassuk J. Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002; 20: 111-118.
4. Ashton AK, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 1997; 23: 165-175.
5. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85.
6. Goldstein DJ, Rampey Jr AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129-135.
7. National Heart, Lung, and Blood Institute Obesity Education Initiative. The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute: Rockville, MD, October 2000. NIH Publication Number 00-4084.
8. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4): S29-S33.
9. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998; 22 (Suppl 1): S18-S28.
10. WHO Global Strategy on Diet Physical Activity and Health: South-East Asia Regional Consultation Meeting Report, New Delhi, India, 10-12 March 2003.
11. WHO Regional Office for the Western Pacific/International Association for the Study of Obesity/International Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Health Communications Australia: Sydney, 2000.
12. Brownell KD. The LEARN Program for Weight Management, 10th edn. American Health Publishing Co: Dallas, Texas, 2004.
13. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208.
14. Meston CM, Frohlich PF. Update on female sexual function. Curr Opin Urol 2001; 11: 603-609.
15. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888-893.
16. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin N Am 1998; 27: 877-902.
17. Adolfsson B, Elofsson S, Rossner S, Unden AL. Are sexual dissatisfaction and sexual abuse associated with obesity? A population-based study. Obes Res 2004; 12: 1702-1709.
18. Arenton LW. Factors in the sexual satisfaction of obese women in relationships. Electron J Hum Sexuality 5, Available at: http:// www.ejhs.org/volume5/Areton/TOC.htm. Accessed August 16, 2005.
19. Kolotkin RL, Head S, Hamilton M, Tse CK. Assessing impact of weight on quality of life. Obes Res 1995; 3: 49-56.
20. Werlinger K, King TK, Clark MM, Pera V, Wincze JP. Perceived changes in sexual functioning and body image following weight loss in an obese female population: a pilot study. J Sex Marital Ther 1997; 23: 74-78.
21. Rand CS, Kuldau JM, Robbins L. Surgerry for obesity and marriage quality. JAMA 1982; 247: 1419-1422.
22. Turcato E, Zamboni M, De Pergola G, Armellini F, Zivelonghi A, Bergamo-Andreis IA et al. Interrelationships between weight loss, body fat distribution and sex hormones in pre- and postmenopausal obese women. J Intern Med 1997; 241: 363-372.
23. Dixon JB, O'Brien PE. Neck circumference a good predictor of raised insulin and free androgen index in obese premenopausal women: changes with weight loss. Clin Endocrinol 2002; 57: 769-778.
24. Hainer V, Kunesova M, Stunkard AJ, Parizkova J, Stich V, Mikulova R et al. The within-pair resemblance in serum levels of androgens, sex-hormone binding globulin and cortisol in female obese identical twins - effect of negative energy balance induced by very low-calorie diet. Horm Metab Res 2001; 33: 417-422.
25. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556-560.
26. Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin Proc 2004; 79 (Suppl 4): S19-S24.
27. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47: 339-351.
28. Davis S, McCloud P, Strauss B, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1996; 21: 227-236.
29. Stunkard AJ, Stinnett JL, Smoller JW. Psychological and social aspects of the surgical treatment of obesity. Am J Psychiatry 1986; 143: 417-429.
30. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198.
31. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505-512.
32. Wadden TA, Foster GD, Wang J, Pierson RN, Yang MU, Moreland K et al. Clinical correlates of short- and long-term weight loss. Am J Clin Nutr 1992; 56 (Suppl 1): S271-S274.
33. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-2125.
34. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4): S34-S37.
35. Sabuncu T, Ucar E, Birden F, Yasar O. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab 2004; 17: 103-107.
36. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-688.
37. Baldwin DS. Depression and sexual dysfunction. Br Med Bull 2001; 57: 81-99.
38. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997; 33: 747-753.